A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf, Fawad; Dupuy, Sheena L; Tauhid, Shahamat; Chu, Renxin; Kim, Gloria; Tummala, Subhash; Khalid, Fariha; Weiner, Howard L; Chitnis, Tanuja; Healy, Brian C; Bakshi, Rohit.
J Neurol Sci
; 383: 221-229, 2017 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-29146095
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics.
Increased body mass index is associated with specific regional alterations in brain structure.
The substrate of increased cortical FA in MS: A 7T post-mortem MRI and histopathology study.
Gray matter asymmetries in aging and neurodegeneration: A review and meta-analysis.
A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis.
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study.
Common pattern of gray-matter abnormalities in drug-naive and medicated first-episode schizophrenia: a multimodal meta-analysis.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.